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Well-to-moderately diﬀerentiated neuroendocrine tumors of gastroesophageal and pancreatic origin (GEP-NETs) with liver
metastasis are a heterogeneous group of malignancies for which a range of therapeutic options have been employed. Surgical
resection of hepatic metastases or hepatic artery embolization may be beneﬁcial in patients with hepatic-predominant metastatic
disease. Patients with “carcinoid” syndrome and syndromes associated with functional pancreatic NET (PNET) can be eﬀectively
treated with somatostatin analogs. On the other hand, the eﬃcacy of systemic chemotherapy for these patients is limited. A
placebo-controlled, double-blind, prospective, and randomized study showed that octreotide LAR improves progression-free
survival in patients with advanced midgut functional “carcinoids.” In patients with advanced pancreatic NET, randomized,
placebo-controlled studies have recently demonstrated that treatment with the tyrosine kinase inhibitor sunitinib or with mTOR
inhibitor everolimus is associated with improved progression-free survival. Based on these studies, octreotide LAR, sunitinib, or
everolimus are now considered as ﬁrst-line therapeutic options in patients with advanced NET. Future studies will likely further
deﬁne the role of these agents in patients with carcinoid liver metastasis and pancreatic NET liver metastasis.
1.Introduction
Neuroendocrine tumors of gastroesophageal and pancreatic
origin (GEP-NETs) are a heterogeneous group of tumors
characterized by their secretion of hormones or vasoactive
peptides often resulting in speciﬁc hormone hyperfunction
syndromes. NETs have recently been shown to be more
common than previously suspected. In an analysis of
the Surveillance, Epidemiology, and End Results (SEER)
database, the estimated age-adjusted annual incidence of
NET in 2004 was 5.25 per 100,000 people [1].
The prognosis and management of GEP-NETs is guided
by histological classiﬁcation. As a general rule, tumors with
a high grade (grade 3), a mitotic count of more than
20 per 10 high-powered ﬁelds, or a Ki-67 proliferation
index of more than 20% represent highly aggressive ma-
lignancies with a short clinical course and poor survival
outcomes. The approach for these tumors is similar to
that for small cell lung cancer and is not discussed in this
review.
The focus of this review is the well-to-moderately diﬀer-
entiated GEP-NETs. These tumors can be subclassiﬁed into
two general categories: pancreatic neuroendocrine tumors
(PNETs)andothers,mostlyarisingintheintestine,andoften
associated with the “carcinoid” syndrome. The terminology
of “endocrine tumor” is replacing “neuroendocrine tumor”
in pancreatic neuroendocrine tumors. And carcinoid is often
linked to the secretion of serotonin and other vasoactive
peptites resulting in “carcinoid” syndrome. This syndrome
is manifested by episodic ﬂushing, wheezing, diarrhea,
and eventual right-sided valvular heart disease. Syndromes
associated with hormone-secreting PNET can be manifested
in insulinoma, glucagonoma, vasoactive intestinal peptide
(VIP)-oma, and gastrinoma.
The majority of PNET occurs sporadically, but these
tumors can also belong to a number of inherited syndromes2 International Journal of Hepatology
associated with mutations in well-studied oncogenes and
tumor suppressor genes. These syndromes include multiple
endocrine neoplasia (MEN) types 1 and 2, von Hippel-
Lindaudisease,andtuberoussclerosis[2].PatientswithNET
with such syndromes may represent subgroups particularly
responsivetonoveltherapiestargetingtheunderlyinggenetic
defect or pathway.
GEP-NETs typically have an indolent natural history,
even in the setting of metastasis. The treatment of patients
with localized NET is primarily surgical. There are no
data that demonstrate a beneﬁt associated with adjuvant
therapies. However, GEP-NETs commonly metastasize to
liver, with up to 44% of patients developing neuroendocrine
liver metastasis (NELM) over the course of their disease
[3]. This review summarizes the current approach to NELM
based on clinical trials in the past 10 years, emphasizing the
diﬀerences between NELM arising from carcinoid and those
from PNET.
2. Locoregional Therapies
2.1. Surgical Resection. Symptom control and improved
quality of life and overall survival can be achieved by the
reduction of circulating hormone levels via functional hor-
monal blockade, transarterial chemoembolization (TACE),
or radiofrequency thermal ablation (RFA), thus obviating
surgery. However, hepatic resection is often considered in
patientswithlimitedhepaticdisease.Ifmorethan90%ofthe
tumor mass can be removed, these patients have an outcome
similar to those with complete resection (resection of all
visible hepatic tumors) [4, 5].
Mayo et al. [6] reported the outcomes of 339 patients
from 8 major hepatobiliary centers who underwent surgical
management for neuroendocrine liver metastasis (NELM)
from 1985 to 2009. Major hepatectomy was performed
in 45% of patients, and 14% underwent a second liver
operation. Median survival was 125 months, with overall
5- and 10-year survival of 74%, and 51%, respectively.
Disease recurred in 94% of patients at 5 years. Patients
with hormonally functional NET who had R0/R1 resec-
tion beneﬁted the most from surgery (P = 0.01). In a
multivariate analysis, synchronous disease, nonfunctional
NET hormonal status, and extrahepatic disease were inde-
pendent predictors of worse survival (P<0.05). Thus,
while surgical resection for NELM is associated with
prolonged survival, the majority of patients will develop
recurrent disease. Patients with hormonally functional hep-
atic metastasis without prior extrahepatic or synchronous
disease derive the greatest survival beneﬁt from surgical
management.
2.2. Radiofrequency Thermal Ablation (RFA). Mazzaglia et
al. [7] reported a prospective trial of 80 RFA sessions
which was performed in 63 patients with NELM. Tumor
types included 36 “carcinoid”, 18 pancreatic islet cell, and 9
medullary thyroid cancer. RFA was performed 1.6 years after
the diagnosis of liver metastases. Median number of lesions
treated was 6. The majority (49%) underwent 1 ablation
session, and 14 (22%) had repeat sessions caused by disease
progression. Fifty-seven percent of patients exhibited symp-
toms. One week postoperatively 92% of patients reported
at least partial symptom relief, and 70% had signiﬁcant
or complete relief. Duration of symptom control was 11
months. Larger dominant liver tumor size and male gender
adversely impacted survival (P<0.05). Median survival
times were 11.0 years after diagnosis of primary tumor, 5.5
years after diagnosis of NELM, and 3.9 years after ﬁrst RFA.
RFA, therefore, provides eﬀective local control with prompt
symptomatic improvement.
2.3. Liver Transplantation. If metastases are limited to the
liver, orthotopic liver transplantation (OLT) is a viable
treatment option [8]. OLT is currently oﬀered to patients
with unresectable metastases or for palliation of medically
uncontrollable symptoms. Very few centers had reported
experience representing more than 10 patients. Lehnert
reviewed 103 cases who underwent OLT for metastases of
NET in the largest review so far. Overall, 2-year and 5-year
survival for all 103 patients was 60% and 47%, respectively,
but recurrence-free 5-year survival did not exceed 24%.
Three favorable prognostic factors were identiﬁed: age less
than 50 years old, primary tumor location in lung or
bowel, and pretransplant somatostatin therapy. In contrast,
extensive abdominal operations were associated with poor
prognosis. Thus, liver transplantation may be indicated
in highly selected patients to provide immediate relief of
otherwise intractable pain or hormone-related symptoms.
OLT has no clear role in the routine treatment of patients
with NET due to relatively high rates of tumor recurrence
[9–11].
2.4. Transarterial Embolization (TAE)/Transarterial Che-
moembolization (TACE). Hepatic arterial embolization is
commonly used as a palliative technique in patients with
hepatic metastases who are not candidates for surgical
resection. Hepatic artery embolization is based on the
principle that tumors in the liver derive most of their
blood supply from the hepatic artery, whereas healthy
hepatocytes derive most of their blood supply from the
portal vein. Embolization response rates are measured either
by a decrease in hormonal secretion or by radiographic
regressionandaregenerallygreaterthan50%[12,13].Inone
of the largest series of 81 patients underwent embolization
or chemoembolization for tumors labeled as “carcinoids”
(likely of intestinal origin), the median duration of response
was 17 months, and the probability of progression-free sur-
vivalat1,2,and3yearswas75%,35%,and11%,respectively
[12].
Objective tumor responses have been noted in 33% to
67% of patients (Table 1). The variation of objective tumor
response is related to the heterogeneous nature of tumors,
various combination of cytotoxic agents, uncontrolled con-
comitant use of somatostatin analogues, and the diﬀerence
in hepatic tumor burden.International Journal of Hepatology 3
Table 1: Selected clinical studies of transarterial embolization (TAE)/transarterial chemoembolization (TACE) in metastatic NET.
Author (yr) No. of
patients Disease Therapy Complete/partial
response
Ruszniewski et al. [14] (1993) 24 Carcinoid/PNET TACE 33%
W¨ angberg et al. [15] (1996) 40 Carcinoid TAE 42.5%
Gupta et al. [12] (2003) 81 Carcinoid TACE/TAE 67%
Strosberg et al. [16] (2006) 84 Carcinoid/PNET TAE 48%
Marrache et al. [17] (2007) 38 Carcinoid/PNET TACE/TAE 37%
Ho et al. [18] (2007) 33 Carcinoid/PNET TACE/TAE 46%
Table 2: Selected clinical trials of cytotoxic chemotherapy in advanced PNET∗∗.
Regimen No. of
patients
Tumor
response
rates (%)
Median
PFS
month
Complete/partial
response Author (yr)
Prospective studies
C h l o r o z o t o c i n 3 33 01 7 1 8 M o e r t e l e t a l . [ 19] (1992)
STZ + 5FU 33 45 14 16.8
STZ + DOX 36 69 18 26.4
DTIC 50 34 NR 19.3 Ramanathan et al. [20] (2001)
Retrospective studies
STZ + 5FU + DOX 84 39 18 37 Kouvaraki et al. [21] (2004)
TMZ various
chemotherapy 53 34 13.6 35.3 Kulke et al. [22] (2009)
TMZ + Capecitabine 30 70 18 NR Strosberg et al. [23] (2010)
∗∗Several of the early studies often assessed tumor response and PFS by clinical and not imaging parameters.
PFS: progression-free survival, STZ: streptozocin, 5FU: 5-ﬂurouracil, DOX: doxorubicin, DTIC: dacarbazine, TMZ: temozolomide, NR: not reported.
Recent research has investigated the use of 90Y radioem-
bolization to treat unresectable NELM. Kennedy et al. [24]
reported that imaging response demonstrated stable lesions
in 22.7%, partial response in 60.5%, complete response in
2.7%, and progressive disease in 4.9% of patients with only
mild associated toxicity. The median survival from time of
treatment was 70 months. Objective respond rate (complete
and partial response) were observed in 50% of patients in a
prospective studies, in which 32 patients were treated with
90Y microspheres [25].
3. Systemic Therapies
3.1. Somatostatin Analogs. Most neuroendocrine tumors
(>80%) express a high density of somatostatin receptors
(SSTR 1–5). Native somatostatin has not been useful in
clinical practice due to its short half-life (<2m i n u t e s ) .I n
1980, Bauer et al. synthesized a somatostatin analog called
octreotide, constituting an octapeptide with 3 unnatural
amino acids, whereby the compound became resistant to
metabolic degradation and presented a half-life of 3 to 4
hours in circulation. This peptide binds with high aﬃnity to
SSTR2 and SSTR5 and, therefore, inhibits the secretion of
peptides and amines from neuroendocrine cells. In an initial
study, the subcutaneous administration of the somatostatin
analogoctreotide,administeredatadosageof150mg3times
a day, improved the symptoms of “carcinoid” syndrome in
88% of patients [26].
Octreotide has been widely used in oncology for almost
3 decades and is the most eﬀective drug in inhibiting clinical
symptoms related to hypersecretion of amines and peptides
in NET. A long-acting depot form of octreotide (octreotide
LAR), which can be administered on a monthly basis, has
gained popularity. Octreotide therapy results in remission
or stabilization of tumor markers, such as serotonin and
chromogranin A, in approximately 60% to 70% of patients
[27, 28].
PROMID [29] is the ﬁrst randomized prospective trial
demonstratingapossibleantitumoreﬀectforoctreotideLAR
compared with a placebo in patients with well-diﬀerentiated
neuroendocrine tumors of midgut origin. A total of 85
patients with inoperable or metastatic well-diﬀerentiated
midgut neuroendocrine tumors (carcinoid tumor) were
randomized to receive either octreotide LAR 30mg monthly
or placebo. Median time to tumor progression was sig-
niﬁcantly longer for patients receiving octreotide (14.3
versus 6 months). This study supports an antiproliferative
eﬀect in well-diﬀerentiated midgut carcinoid tumors, with
stabilization being the most frequently observed therapeutic
response. However, only less than 10% tumor mass in
the liver along with resected primary tumors responded to
treatment. There was no signiﬁcant diﬀerence in time to
tumor progression between octreotide LAR and placebo in4 International Journal of Hepatology
Table 3: Selected randomized trials of targeted therapy in advanced neuroendocrine tumors.
Regimen No. of
patients
Tumor
response
rates (%)
Median PSF
(months)
%o f
NELM
Author
(yr)
PNET
Sunitinib 37.5mg po qd 86 9 11.4
(P<0.001)
71
(61/86)
Raymond et
al. [35]
(2011)
Placebo (+ best supportive care) 85 0 5.5 54
(46/85)
Everolimus 10mg po qd 207 5 11
(P<0.001)
92
(190/207)
Yao et al. [36]
(2011)
Placebo (+ best supportive care) 203 2 4.6 92
(187/203)
Everolimus 10mg po qd
Everolimus 10mg po qd +
Bevacizumab 10mg/kg
every other week
GALGB
80701 Ongoing
Carcinoid
Octreotide LAR 42 2 14.3
(P<0.001)
83
(35/42)
Rinke et al.
[29] (2009)
Placebo 43 2 6.0 88
(38/43)
Everolimus + octreotide LAR 187
Radiant-2
accrual
completed
Final report
pending
Placebo + octreotide LAR 191
Octreotide + bevacizumab SWOG
S0518
Octreotide + placebo
patients with larger tumor burden. The authors concluded
that newly diagnosed NET with a low hepatic tumor burden
and resected primary tumor were candidates for treatment
with octreotide LAR.
The high rate of somatostatin receptor expression in
NETs provides the rationale for peptide receptor radionu-
clide therapy (PRRT) as a treatment modality for patients
with inoperable or metastatic disease. Several radiolabeled
somatostatin analogs have been developed to treat patients
with somatostatin receptor-positive metastatic tumors. The
most frequently used radionuclides include yttrium (90Y)
and lutetium (177Lu), which diﬀer from one another in terms
of emitted particles, particle energy, and tissue penetration.
90Ye m i t sβ-radiation has a range of 12mm, and 177Lu
emits both β-radiation and γ-radiation and has a range of
2mm. 177Lu-DOTA, Tyr3-octreotate has since been utilized
in the treatment of over 500 patients with GEP-NETs.
Eﬃcacy results, reported for 310 patients and 89% (276/310)
presented liver metastasis, suggest an overall tumor response
rate of up to 30%. However, all PRRTs using yttrium (90Y)
andlutetium(177Lu)arenotrandomized,prospectivestudies
and majority of patients are carcinoid [30–33].
3.2. Cytotoxic Chemotherapy. In a Phase II/III study of
249 patients with advanced “carcinoid” tumors, patients
were randomized to receive either streptozocin/5-FU or 5-
FU/doxorubicin [34] .T h er e s p o n s er a t e sw e r e1 6 %a n d
15.9%, respectively. Although there was a slightly longer
survival time associated with streptozocin/5-FU (24.3 versus
15.7 months) in this trial, over one-third of the patients
treated with streptozocin developed renal toxicity. Thus,
streptozocin-based regimens are not recommended in the
ﬁrst-line treatment of metastatic “carcinoid” tumors.
However, patients with advanced PNET may respond
well to treatment with streptozocin and other alkylating
agents. In a randomized trial, the combination of strep-
tozocin and doxorubicin was associated with an overall
response rate of 69% and a survival beneﬁt, with median
overall survival of 2.2 years [19]. A retrospective analysis of
84 patients with either locally advanced or metastatic PNET
receiving a three-drug regimen of streptozocin, 5-FU, and
doxorubicin showed that this regimen was associated with
an overall response rate of 39% and a median survival of 37
months [21].
Temozolomide is an orally alkylating agent with a mech-
anism of action similar to streptozocin and dacarbazine.
Retrospective studies suggest comparable progression-free
survival (PFS) and overall survival (OS) between strep-
tozocin and temozolomide-based regimens in patients
with advanced PNET (Table 2). Prospective studies usingInternational Journal of Hepatology 5
temozolomide-based regimens in patients with advanced
PNET are ongoing.
3.3.TargetedTherapiesforPancreaticNeuroendocrineTumors.
Studies of targeted therapies in PNET have, to date, focused
primarily on inhibitors of the vascular endothelial growth
factor (VEGF) or mammalian target of rapamycin- (mTOR)
signaling pathways. Two phase III randomized studies sug-
gested that treatment with these agents is associated with
improvements in progression-free survival (PFS).
3.4. VEGF Pathway Inhibitors. Bevacizumab which targets
VEGF and three tyrosine kinase inhibitors: pazopanib,
sorafenib, and sunitinib—all with activity against VEGF
receptor(VEGFR)—havebeenevaluatedinprospectivetrials
of patients with advanced PNET.
Bevacizumab is a recombinant humanized monoclonal
antibody that binds to and neutralizes the biologic activity of
human VEGF-A. In a randomized phase II study conducted
at M.D. Anderson, 44 patients on stable doses of octreotide
were randomly assigned to 18 weeks of treatment with
bevacizumab or pegylated interferon alfa-2b (PEG IFN). A
rapid and sustained decrease was observed in tumor perfu-
sion following treatment with octreotide and bevacizumab,
as measured in functional computed tomography. Clinical
activity was evident by a response rate of 18% and an
improved PFS rate at week 18 (95% versus 68%; P = 0.02).
Bevacizumab therapy therefore provides an advantage in
objective responses, reduction of tumor blood ﬂow, and PFS
in patients with carcinoid compared to PEG IFN treatment
[37].
NETs frequently express VEGFR-2 and platelet-derived
growth factor receptor receptor-β (PDGFR-β). Sorafenib,
a small-molecule inhibitor of the VEGFR-2 and PDGFR-β
tyrosine kinase domains, is a rational targeted therapy to
be evaluated in NET. Hobday, et al. [38]r e p o r t e dap h a s e
II study in 2007 ASCO using sorafenib in patients exposed
to prior interferon and prior or concurrent octreotide at a
stable dose. Patients received sorafenib 400mg orally BID.
A total of 93 patients were enrolled: (50 carcinoid and 43
PNET). For patients evaluable for the primary endpoint, 4 of
41(10%)carcinoidpatientsand4of41(10%)PNETpatients
had a partial response (PR). There were 3 minor responses
(MR = 20–29% decrease in sum of target lesion diameters)
in carcinoid patients and 9 MRs in PNET patients and this
led to PR + MR rate of 17% for carcinoid patients and 32%
for PNET patients. Sorafenib at 400mg orally twice a day in
this study demonstrated modest activity in metastatic NET.
VEGF is a key driver of angiogenesis in PNET. Tis-
sue from malignant PNET also shows widespread expres-
sion of PDGFRs α and β, stem-cell factor receptor (c-
kit), and VEGFR-2 and VEGFR-3. Sunitinib inhibits these
kinases and delays tumor growth in a RIP1-Tag2-transgenic
mouse model of pancreatic islet-cell tumors by reducing
endothelial-cell density and pericyte coverage of tumor
vessels.
Sunitinib was evaluated in a multi-institutional phase II
study enrolling 109 patients with advanced NET. Patients
received sunitinib, administered orally at 50mg once daily
for4weeks,followedbya2-weekoﬀperiod.Partialresponses
were observed in 2% of the carcinoid cohort and 16% of
the PNET cohort [39]. Based on the encouraging response
rateinthisphaseIIstudy,aninternationalrandomizedphase
III study was conducted to conﬁrm the activity of sunitinib
in PNET. The study was discontinued prior to a planned
interim analysis after enrollment of 171 patients, 86 of them
received sunitinib, and 85 received placebo. The trial was
terminatedearlybecauseoftheriskofseriousadverseevents,
disease progression, and death among patients receiving
placebo. The early discontinuation of the study precluded
the deﬁnitive conclusion on diﬀerences in PFS durations
between the treatment and placebo groups. Nevertheless,
analysis of the available data demonstrated that treatment
with sunitinib was associated with a remarkable median PFS
of 11.4 months, as compared with 5.5 months for placebo
(P = 0.0001) [35].
Pazopanib is an oral tyrosine kinase inhibitor of VEGFR,
PDGFR, and KIT with both antiangiogenic and antitu-
moral activity. Pazopanib was evaluated in a prospective
study enrolling 51 NET patients (29 with PNET and 22
with carcinoid) on stable doses of octreotide-LAR. Patients
received pazopanib at a dose of 800mg daily. The response
rate among patients with PNET was 17%; no patients with
carcinoid experienced a radiographic response (by RECIST).
PFS rate at week 24 was 76% (80% PNET and 71%
carcinoid).MedianPFStimeswere12.7and11.7months,for
carcinoid and PNET patients, respectively. Encouraging PFS
durations in both carcinoid and PNET patients in this study
suggested that treatment with pazopanib and octreotide
seemed feasible and associated with tumor regression in
patients with PNET [40].
3.5. mTOR Inhibitors. mTOR is a serine-threonine kinase
that participates in the regulation of cell growth, prolifera-
tion,andapoptosis.SignalingthroughthePI3K/AKT/mTOR
pathway leads to increased translation of proteins regulating
cell-cycle progression and metabolism. This enzyme also
mediates downstream signaling from a number of pathways,
including the VEGF and insulin-like growth factor (IGF)
signaling implicated in NET growth. The inhibition of
mTOR prevents phosphorylation of key cell-cycle control
proteins, leading to G1 growth arrest.
Temsirolimus and everolimus are rapamycin derivatives
which were evaluated in NET. Weekly intravenous tem-
sirolimus was associated with a response rate of 5.6% in
a study of 37 patients with advanced progressive NET.
Outcomes were similar between patients with carcinoid and
PNET [41].
Everolimus was initially evaluated in a single-institution
study, in which 30 patients with “carcinoid” tumors of
intestinal origin and 30 with pancreatic PNET received doses
o f5o r1 0 m gd a i l yp l u sd e p o to c t r e o t i d e( 3 0 m ge v e r y4
weeks). The overall tumor response rate in evaluable patients
was 17% in carcinoid and 27% in PNET [42].
In a follow-up international phase II study (RADIANT-
1), 160 patients with advanced PNET and evidence of6 International Journal of Hepatology
RECIST-deﬁned progression following chemotherapy were
enrolled. In this nonrandomized study, treatment with
everolimus was associated with an overall response rate of
4.4% and PFS duration of 16.7 months in those patients
receiving octreotide. Among patients who did not receive
octreotide, the response rate was 9.6%, and the PFS duration
was 9.7 months [43].
A subsequent phase III study randomized 410 patients
with progressive advanced PNET (RADIANT-3) to ever-
olimus or placebo. This study demonstrated signiﬁcant
improvements in PFS (the primary endpoint) associated
with everolimus as compared to placebo [(11 months versus
4.6 months (P<0.0001)]. The overall tumor response rate
associated with everolimus in this study was 5% [36]. A
subgroup analysis of Japanese patients (23 patients received
everolimus and 17 patients were in placebo arm) in the
same RADIANT-3 study showed a signiﬁcant 17 months
improvement in PFS (19.45 versus 2.83 months) and an
81% risk reduction of progression or death (HR 0.19, 95%
CI 0.08–0.48, P<0.001) [44]. Phase III-randomized trials
of biological targeted therapy in advanced neuroendocrine
tumors are summarized in Table 3.
3.6. Combination of Target Therapies. Ongoing studies are
evaluating combinations of targeted agents in patients
with advanced neuroendocrine tumors. The combination of
everolimus + bevacizumab was shown to be well tolerated
and associated with antitumor activity (overall response rate
26%) in an initial phase II study enrolling patients with
low- or intermediate-grade neuroendocrine tumors [43].
Other combination-advanced PNETs includes everolimus +
temozolomide [45] and everolimus + octreotide [42].
4. Conclusions
Diﬀerent therapeutic options have been employed for well-
to-moderately diﬀerentiated NELM. Surgical resection of
hepatic metastases or hepatic artery embolization can be
helpful in patients with hepatic-predominant metastatic dis-
ease. Symptoms of hormonal excess, such as “carcinoid” syn-
drome and syndromes associated with functional PNET, can
be eﬀectively treated with somatostatin analogs. Treatment
with the somatostatin analog octreotide has been shown to
improve progression-free survival in patients with advanced
midgut carcinoid tumors. Patients with NELM may also
respond to treatment with streptozocin or temozolomide-
based therapy but need to be reassessed using standard cri-
teria of response. In patients with advanced PNET, random-
ized, placebo-controlled studies have recently demonstrated
that treatment with the tyrosine kinase inhibitor sunitinib
or with the mTOR inhibitor everolimus is associated with
improved PFS. Initial phase II studies have also suggested
activityassociatedwithVEGFpathwayandmTORinhibitors
in patients with neuroendocrine tumors of other origins
including intestinal “carcinoids.” Future studies will likely
deﬁne the utility of combinations of these agents in the
treatments of patients with NELM.
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